SCHEMBL3440241

SCHEMBL3440241

Cc1cc(Br)cc(C)c1S(=O)(=O)Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA12 O43570 1/20 0.37
CA4 P22748 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
NMT1 P30419 4/20 0.34
RAPGEF4 Q8WZA2 4/20 0.33
MAPK1 P28482 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
FLT1 P17948 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7608 0.80 CA1 (0.52) CA1CA2CA12CA4CA7
SCHEMBL21550418 0.79 FABP4 (0.45) CA1CA2CA12CA4CA7
SCHEMBL3111382 0.78 MAPK1 (0.47) CA1CA2MMP1MMP2MMP9
SCHEMBL11139384 0.78 RAPGEF4 (0.39) CA1CA2CA12CA4CA7
SCHEMBL3609619 0.78 GAA (0.40) CA1CA2CA12CA4CA7
SCHEMBL13649887 0.76 CYP3A4 (0.48) CA1CA2CA12CA4CA7
SCHEMBL22396636 0.76 FABP4 (0.42) CA1CA2MMP1MMP2MMP9
SCHEMBL30851364 0.76 LMNA (0.43) CA1CA2CA12CA4CA7
SCHEMBL640928 0.76 PTGS1 (0.38) CA1CA2CA12CA4CA7
SCHEMBL9521335 0.76 L3MBTL1 (0.42) CA1CA2CA12CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613384-A 2-Amino substituted aza-heteroaryl compounds as HPK1 inhibitors and uses thereof 中国药科大学 2025-03-14 CN disclosed
CN-113861110-B Polysubstituted sulfonamide compound, preparation method and medical application thereof 中国药科大学 2024-03-01 CN disclosed
CN-113861110-A Polysubstituted sulfonamide compound, preparation method and medical application thereof 中国药科大学 2021-12-31 CN disclosed
US-10544095-B2 3-indol substituted derivatives, pharmaceutical compositions and methods for use PFIZER INC. (US) 2020-01-28 US disclosed
US-20180222862-A1 NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE ITEOS THERAPEUTICS (BE) 2018-08-09 US disclosed
EP-3334733-A1 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE Pfizer Inc (US) 2018-06-20 EP disclosed
WO-2017025868-A1 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE PFIZER INC. (US) 2017-02-16 WO disclosed
EP-2188251-B1 ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY BOEHRINGER INGELHEIM INT (DE) 2015-04-29 EP disclosed
EP-2066659-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2013-08-28 EP disclosed
US-8450306-B2 Bradykinin B1-receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
WO-2009021758-A1 ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO disclosed
EP-2025675-A1 Arylsulfonamides with analgetic activity Boehringer Ingelheim International GmbH (DE) 2009-02-18 EP disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 US disclosed
WO-2008022945-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 WO disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS SULT2A1, STS, SULT1A1 CA1 2473/4885CA2 972/4885CA12 1876/4885
US-10544095-B2 3-indol substituted derivatives, pharmaceutical compositions and methods for use TDO2, IDO1, IDO2 CA1 3816/4885CA2 3245/4885CA12 4445/4885
US-20180222862-A1 NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TDO2, IDO1, IDO2 CA1 3464/4885CA2 3049/4885CA12 4354/4885
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR CA1 4880/4885CA2 4647/4885CA12 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.